ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO458

Outcome Study Among Hospitalized Symptomatic COVID-19 Patients Who Required Chronic vs. Acute Hemodialysis (HD)

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Pham, Phuong-Chi T., UCLA Medical Center Olive View, Sylmar, California, United States
  • Alghussein, Mohammad Samir, UCLA Medical Center Olive View, Sylmar, California, United States
  • Villano, Svetlana O., UCLA Medical Center Olive View, Sylmar, California, United States
  • Singh, Nisha Mei, UCLA Medical Center Olive View, Sylmar, California, United States
  • Mendoza, Susana M., UCLA Medical Center Olive View, Sylmar, California, United States
  • Jafari, Golriz, UCLA Medical Center Olive View, Sylmar, California, United States
  • Kamarzarian, Anita, UCLA Medical Center Olive View, Sylmar, California, United States
  • Pham, Phuong-Thu T., University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
Background

Mortality among patients admitted for COVID19 infections who develop acute kidney injury (AKI) and require dialysis support has been reported to be ≥60-70%. Data are lacking regarding how chronic HD patients with an impaired immune system may: 1) mount an inflammatory response to COVID19 infection and 2) survive the infection compared with those who require acute HD for AKI. We evaluated ferritin levels, hospital length of stay (LOS), and mortality rates among chronic HD patients and those who required acute HD during hospitalization for COVID19-related symptoms.

Methods

Inclusion: All patients hospitalized for COVID19-related symptoms who received HD at OV-UCLA Medical Center from January to December 2020. Data collection: Baseline characteristics: age, gender, body mass index (BMI), comorbidities (diabetes mellitus, hypertension, underlying chronic obstructive lung disease or asthma, history of malignancy, and heart failure). Medications: use of any inhibitor of the renin angiotensin aldosterone system. Lab studies: albumin, ferritin, basic chemistry. Hospital LOS and death from any cause. Data analysis: Ferritin levels, hospital LOS, and mortality among chronic and acute HD patients.

Results

See Figure

Conclusion

Among our hospitalized symptomatic COVID19 patients requiring HD support:
1. Ferritin levels were comparable between chronic HD and previously nondialysis patients who required acute HD support.
2. Chronic HD patients had shorter hospital LOS compared with those requiring acute HD (6.2 + 5.7d vs. 35.3 + 31.3d). The 2 groups had similar serum sodium, albumin, and ferritin levels.
3. Mortality was <5% (compared with 1.5% for the US population).among chronic HD patients and 58% among those who developed AKI requring acute HD.
4. Incidentally, BMI among current COVID19 cohort was 30.6 + 8.8 compared with 26.4 + 5.8 Kg/m2 from our 70 non-COVID dialysis patients included in a different study (p-value <0.001).